Publications/ Singapore
 |
| Internal Publication |
May 2005 |
| By Ames Gross and Rachel
Weintraub |
| Despite
the country’s small size, Singapore boasts a highly-developed
economy and serves as an Asian hub for numerous medical
companies. In total, Singapore’s medical device
and pharmaceutical markets are estimated at over $800
million. Leading pharmaceutical companies, such as GlaxoSmithKline,
Pfizer, Eli Lilly and Bristol-Myers Squibb, have established
a presence in Singapore and continue to expand their
facilities. Pfizer chose Singapore for its first large-scale
active pharmaceutical ingredient manufacturing facility
in Asia, while GlaxoSmithKline set up its first Asia
region preclinical research establishment in Singapore.
In response to the growth of Singapore’s medical
industry, the Health Sciences Authority has been making
great efforts to boost its regulatory expertise and improve
the pharmaceutical and medical device regulatory environment
in Singapore. |
| |
| Published in Clinica,
a publication of PJB Publications, Ltd. |
November 1993 |
| By Ames Gross |
|
| Singapore is one of the most technologically
advanced societies among the ASEAN countries. Its extensive
healthcare system, high health standards, comprehensive
medical facilities and advanced medical market make the
small city-state an ideal place for medical market investment.
The Singapore Ministry of Health and the Singapore Economic
Development Board (EDB) are responsible for the Singapore’s
healthcare industries. They are working to promote Singapore
as the premier regional medical center in order to attract
even more foreign investors of specialized medical equipment.
This article gives an overview of Singapore’s medical
device market, healthcare system and the business climate
for foreign medical suppliers. |
|
Back to Top
|
Asia
China & Hong Kong
India
Indonesia
Japan
Korea
Malaysia
The Philippines
Singapore
Taiwan
Thailand
Vietnam
|
